Phase-3 clinical trial enrolment for India's first dengue vaccine to be completed by October: ICMR

India's DengiAll vaccine trial is nearing completion. ICMR scientists anticipate enrolling 10,500 participants by October across 20 Indian centers. The phase III trial assesses the Panacea Biotec's one-shot dengue vaccine. Initial trials showed no safety concerns. Participants will be monitored for two years to evaluate efficacy. This is a crucial step as India currently lacks a licensed dengue vaccine.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/54vZpRP
via IFTTT